Driven by a passion to help patients

Providing solutions for improving ESKD treatment

Providing solutions for improving ESKD treatment 

Patients with chronic kidney disease can develop end stage kidney disease. There are more than four million patients suffering from end-stage kidney disease (ESKD) worldwide. Most of these patients will require hemodialysis for renal replacement therapy. It is imperative for patients to have a well-functioning vascular access for optimal hemodialysis therapy. According to the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, an autogenous arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. Unfortunately, approximately 60% of AVFs develop a venous stenosis at one year, thus preventing optimal hemodialysis from being administered. Currently, there are no therapies that can prevent the formation of AVF stenosis. Our groundbreaking innovations can decrease venous stenosis formation and the need for costly invasive procedures such as angioplasty otherwise needed to maintain the patency and function of AVFs.